We were suddenly hit by the COVID-19 pandemic. I decided to shift the focus of the podcast to cover the pandemic as it was consuming all of us and started to have an impact on patients and physicians, but also on everyone in the general public. I invited Emily Landon, MD, executive medical director of infection prevention and control, University of Chicago, to break down current exposure risk and mortality rates of COVID-19, preventative steps to avoid exposure, and promising therapies on the horizon.
Emily stated that this was a pandemic on this episode almost 2 weeks before The WHO admitted that we are dealing with one. I was fortunate to win an award for this episode. It was a communication award of distinction. I am humbled to win any kind of award, but grateful to Dr. Landon for this one.
This episode was recognized as a Winner of Distinction in the 26th Annual Communicator Award.
Dr Nabhan and Dr Landon have no relevant financial disclosures. Click here to learn more about Emily Landon. This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
